Researchers find new benefits, risks in GLP-1 weight loss drugs
Scientists uncover unexpected benefits and new risks surrounding widely used GLP-1 weight loss medications.
10 independently sourced, verified trend briefs about this subject.
Newsylist includes a story here only after at least four independent sources support it and its brief passes the verification check. The qualifying coverage spans 2 news categories, from Jun 24, 2026 through Aug 19, 2026.
The cards below are ordered newest first. Each opens the underlying timeline, source list, coverage velocity and verification context; raw or extractive-only records are excluded.
Scientists uncover unexpected benefits and new risks surrounding widely used GLP-1 weight loss medications.
Use of GLP-1 weight loss medications has reached a new high in the United States, sparking debate over long-term efficacy and accessibility.
Compounded GLP-1 weight‑loss drugs face mounting scrutiny as doctors and regulators flag safety concerns.
GLP‑1 weight‑loss drugs are reshaping women’s marriage prospects and job markets, while sparking warnings about unseen relationship strain.
GLP-1 weight-loss medications are seeing a massive surge in adoption, sparking debates over side effects and social disclosure.
Recent studies examine the long-term impact of discontinuing GLP-1 weight-loss medications like Ozempic and Wegovy.
New research suggests a 12-week intermittent fasting regimen may support long-term weight maintenance.
New oral GLP-1 receptor agonists are emerging as powerful alternatives to existing weight-loss medications in recent clinical trials.
The Wegovy weight loss pill has launched in the UK, marking the arrival of the first daily oral GLP-1 medication for weight management.
Health professionals are warning against a viral social media trend promoting a gelatin drink as a 'natural Ozempic' for weight loss.